Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma

Blood

Volumn 96, Issue 9, 2000, Pages 3147-3153

  Treon, S P ^a   Maimonis, P ^a   Bua, D ^a   Young, G ^a   Raje, N ^a   Mollick, J ^a   Chauhan, D ^a   Tai, Y T ^a   Hideshima, T ^a   Shima, Y ^a   Hilgers, J ^a   Von Mensdorff Pouilly, S ^a   Belch, A R ^a   Pilarski, L M ^a   Anderson, K C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; MEMBRANE PROTEIN;

ALTERNATIVE RNA SPLICING; ARTICLE; BONE MARROW CELL; GLYCOSYLATION; HUMAN; HUMAN CELL; IMMUNOASSAY; MEMBRANE BINDING; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION;

EID: 0034330930     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.9.3147.h8003147_3147_3153     Document Type: Article

References (51)

1. The epithelial mucin, Muc1, of milk, mammary gland and other tissues
2. Heterogeneity in production, secretion, and glycosylation of Muc1 epithelial mucin by primary cultures of ovarian carcinoma
3. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin
4. The breast tumour-associated epithelial mucins and the peanut lectin binding urinary mucins are coded by a single highly polymorphic gene locus 'PUM'
5. The product of the human Muc1 gene when secreted by mouse cells transfected with the full length cDNA lacks the cytoplasmic tail
6. The breast cancer associated MUC1 gene generates both a receptor and its cognate binding protein
7. Use of murine monoclonal antibody for detection of circulating DF3 plasma antigen levels in breast cancer patients
8. Circulating CA 15-3 antigen levels in non-mammary malignancies
9. Polymorphic epithelial mucin (MUC1) containing circulating immune complexes in carcinoma patients
10. Value of CA 15.3 in breast cancer and comparison with CEA and TPA: A study of specificity in disease free follow-up patients and sensitivity in patients at diagnosis of the first metastasis
11. Detection of polymorphic epithelial mucins in the serum of systemic breast cancer patients using the monoclonal antibody, NCRC-11
12. Use of the Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease
13. Clinical and technical evaluation of ACS BR serum assay of Muc1 gene derived glycoprotein in breast cancer, and comparison with CA 15.3 assays
14. Expression of Muc1 on myeloma cells and induction of HLA unrestricted CTL against Muc1 from a multiple myeloma patient
15. Specific, MHC unrestricted recognition of tumor associated mucins by human cytotoxic T cells
16. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides
17. DF3 antigen, a human epithelial cell mucin, inhibits adhesion of eosinophils to antibody coated targets
18. Episialin (Muc1) inhibits cytotoxic lymphocyte-target cell interaction
19. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2
20. Soluble MUC1 secreted by human epithelial cancer cells mediates immune suppression by blocking T-cell activation
21. A Muc1 mucin secreted from a colon carcinoma cell line inhibits target cell lysis by natural killer cells
22. Prognostic significance of preimmunotherapy serum CA27.29 (MUC1) mucin level after active specific immunotherapy of metastatic adenocarcinoma patients
23. Tissue and tumor distribution of human polymorphic epithelial mucin
24. Phenotypic analysis of human myeloma cell lines
25. Epithelial membrane antigen in hematopoeitic neoplasms
26. MUC1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone
27. Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women
28. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin (MUC1)
29. Humoral immune response to polymorphic epithelial mucin (MUC1) in patients with benign and malignant breast tumours
30. Detection of circulating anti-MUC1 mucin core protein antibodies in patients with colorectal cancer
31. Epitope mapping of Mab B27.29 within the peptide core of the malignant breast carcinoma-associated mucin antigen coding for the human MUC1 gene
32. Epitope fingerprinting using overlapping 20-mer peptides of the MUC1 tandem repeat sequence
33. Summary report on the ISOBM TD-4 workshop: Analysis of 56 monoclonal antibodies against the Muc1 mucin
34. Epitope mapping of anti-Muc1 mucin protein core monoclonal antibodies
35. Importance of the xenogeneic nature of antibodies for tumor immunotherapy
36. Role of interleukin-6 in the proliferation of human multiple myeloma cell lines OCI-My 1 to 7 established from patients with advanced stage of the disease
37. Acquisition of growth autonomy and tumorigenicity by an interleukin-6 dependent human myeloma cell line transfected with interleukin-6 cDNA
38. A mechanism of resistance to glucocorticoids in multiple myeloma: Transient expression of a truncated glucocorticoid receptor mRNA
39. An enzyme linked immunosorbent assay for the measurement of circulating antibodies to polymorphic epithelial mucin (MUC1)
40. Specificity clusters of Muc1-reactive mouse monoclonal antibodies
41. Carcinoma-associated Muc1 detected by immunoradiometric assays
42. Cellular origin and extent of clonal involvement in multiple myeloma: Genetic and phenotypic studies
43. + peripheral blood cells expressing CD38, CD56, and monotypic immunoglobulin light chain
44. CD34+ cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patient specific IgH rearrangements
45. A high frequency of circulating B cells share clonotypic IgH VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single cell and in-situ RT-PCR
46. The blood B cells and bone marrow plasma cells in a patient with multiple myeloma include cells with the same N-ras mutation
47. The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell
48. Circulating clonotypic B cells in the biology of multiple meloma: Speculations on the origin of myeloma
49. In multiple myeloma, circulating hyperdiploid B cells have clonotypic IgH rearrangements and may mediate spread of disease
50. Multicenter phase III study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphoma
51. Iodine-131 tositumomab therapy for previously untreated follicular lymphoma